Human Microbiome Market worth $1,598 million by 2028

Overview of This Study:

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market.

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market’s size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Download PDF Brochure@

Research Study Adopted:

Secondary data:

The secondary sources referred to for this research study include publications from government sources such as the World Health Organization (WHO), Human Microbiome Project (HMP), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA),, Expert Interviews, and MarketsandMarkets Analysis); business magazines and research journals; press releases; and trade, business, and professional associations.

Secondary data was collected and analyzed to arrive at the global human microbiome market’s overall size, which was validated through primary research.

Primary sources:

In the primary research process, various sources from the supply sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, technology & innovation directors, personnel from research organizations, physicians, academic institutes, and related key executives from various key companies and organizations operating in the human microbiome market.

Expected Revenue Surge:

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028. 

Global Growth Influencing Factors:

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market’s growth.

Opportunity: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Request Sample Pages@

North America accounted for the largest share of the human microbiome market.

In 2019, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research & clinical activities are responsible for driving the growth of the market in North America.